Equities analysts expect Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to post $0.68 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Ligand Pharmaceuticals’ earnings. Ligand Pharmaceuticals reported earnings per share of $1.70 during the same quarter last year, which suggests a negative year-over-year growth rate of 60%. The company is scheduled to report its next quarterly earnings report on Thursday, February 6th.
According to Zacks, analysts expect that Ligand Pharmaceuticals will report full year earnings of $3.05 per share for the current year. For the next year, analysts anticipate that the company will post earnings of $4.05 per share. Zacks’ EPS calculations are an average based on a survey of research firms that cover Ligand Pharmaceuticals.
Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.12). Ligand Pharmaceuticals had a return on equity of 7.47% and a net margin of 388.69%. The company had revenue of $24.81 million for the quarter, compared to the consensus estimate of $22.49 million. During the same quarter in the previous year, the firm posted $1.32 EPS. The business’s revenue for the quarter was down 45.7% compared to the same quarter last year.
Shares of NASDAQ:LGND traded up $0.40 on Friday, hitting $106.19. 31,306 shares of the company were exchanged, compared to its average volume of 321,128. The company’s 50 day moving average price is $109.36 and its two-hundred day moving average price is $105.47. Ligand Pharmaceuticals has a one year low of $84.45 and a one year high of $154.25. The company has a debt-to-equity ratio of 0.75, a quick ratio of 32.96 and a current ratio of 33.15. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of 16.89, a PEG ratio of 2.60 and a beta of 1.27.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC increased its stake in Ligand Pharmaceuticals by 188.6% in the second quarter. Tower Research Capital LLC TRC now owns 228 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 149 shares during the period. FTB Advisors Inc. bought a new stake in Ligand Pharmaceuticals in the second quarter valued at about $26,000. Quest Capital Management Inc. ADV bought a new stake in Ligand Pharmaceuticals in the third quarter valued at about $27,000. Benjamin F. Edwards & Company Inc. increased its stake in Ligand Pharmaceuticals by 1,763.6% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 410 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 388 shares during the period. Finally, Quantamental Technologies LLC bought a new stake in Ligand Pharmaceuticals in the second quarter valued at about $51,000.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Recommended Story: Correction
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.